Navigation Links
Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $20 Million of Common Stock and Warrants
Date:5/11/2009

SEATTLE, May 11 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (Nasdaq and MTA: CTIC) (the "Company") today announced that it has sold $20 million of shares of common stock at $1.25 per share and warrants to purchase shares of common stock in a registered offering to a single institutional investor. The Company currently expects to utilize up to $17.8 million in cash currently on hand and/or cash received in connection with this offering to pay for its anticipated tender offer to retire between $83.2 to $89.2 million of its convertible debt. The Company anticipates that the consideration for the tender offer will be in the range of $250 to $300 per $1,000 par value of the bonds.

In connection with the offering, the investor received 30% warrant coverage on the $20 million offering price. The warrants have an exercise price of $1.40 per warrant share, for total potential additional proceeds to the Company of $6.7 million upon exercise of the warrants. The warrants will terminate on May 11, 2014.

In April 2009 CTI received $20 million in gross proceeds upon the sale of its Series 1 Preferred Stock and an additional $3.8 million upon the exercise of associated common stock warrants in May 2009.

Rodman & Renshaw, LLC, a subsidiary of Rodman & Renshaw Capital Group, Inc., (Nasdaq: RODM), acted as the exclusive placement agent for the transaction.

A shelf registration statement relating to the shares of common stock and warrants issued in the offering (and the shares of common stock issuable upon exercise of the warrants) has been filed with the Securities and Exchange Commission (the "SEC") and has been declared effective. A prospectus supplement relating to the offering will be filed with the SEC. Copies of the prospectus supplement and accompanying prospectus may be obtained directly from the Company by contacting Cell Therapeutics, Inc., 501 Elliott Avenue West, Suite 400, Seattle, Washington 98119. This announcement is neither an offer to sell nor a solicitation of an offer to buy any of our shares of common stock or warrants. No offer, solicitation or sale will be made in any jurisdiction in which such offer, solicitation or sale is unlawful.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. The risks and uncertainties include the risk that the investor might not exercise its warrants, the Company might not be able to continue to raise additional capital as needed to fund its operations, and other risk factors listed or described from time to time in the Company's filings with the SEC, including, without limitation, its most recent filings on Forms 10-K and 8-K. Except as required by law, the Company does not intend to update any of the statements in this press release upon further developments.

    Media Contact:

    Dan Eramian
    T: 206.272.4343
    C: 206.854.1200
    E: media@ctiseattle.com
    www.CellTherapeutics.com/press_room


    Investors Contact:

    Ed Bell
    T: 206.272.4345

    Lindsey Jesch Logan
    T: 206.272.4347
    F: 206.272.4434
    E: invest@ctiseattle.com
    www.CellTherapeutics.com/investors


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Cell Therapeutics, Inc. (CTI) to Present at BIO Investor Forum
2. Horizon Therapeutics, Inc. Scheduled to Present at Upcoming BioPartnering Europe Meeting
3. Sontra Medical Corporation Changes Name to Echo Therapeutics, Inc.
4. Cell Therapeutics, Inc. (CTI) CIBC and Rodman & Renshaw Healthcare Conference Presentations to be Webcast
5. Cell Therapeutics, Inc. (CTI) to Report Third Quarter Financial Results on November 8
6. Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and Third Quarter 2007 Financial Results
7. Cell Therapeutics, Inc. (CTI) Appoints Jim Fong as Vice President, Commercial Operations
8. InteKrin Therapeutics, Inc. Appoints Former Amgen Clinical Development Executive Chief Medical Officer
9. Clinical Trial Investigators Update Wall Street on Progress and Prospects of Cell Therapeutics, Inc.s Drug Pipeline
10. Cell Therapeutics, Inc. (CTI) Plans to Submit Supplemental Biologics License Application (sBLA) for ZEVALIN(R) Consolidation of First Remission in Advanced Stage Follicular Lymphoma in 2008
11. Cell Therapeutics, Inc. Announces $6.5 Million Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... (PRWEB) , ... August 16, 2017 , ... TopConsumerReviews.com recently ... Lab Testing . , The healthcare industry in the United States has undergone ... are the days of needing to have a doctor’s order to get a blood ...
(Date:8/16/2017)... Petaluma, CA (PRWEB) , ... August 16, 2017 ... ... donate and distribute $100,000 in AED (Automated External Defibrillator) machines to their local ... an AED device from Arrow Benefits Group. AED machines are an integral part ...
(Date:8/16/2017)... ... ... of A Child” is the creation of published author, Pauline DiBenedetto. , “As my mother ... was in such great pain, my mother thought that her time has come. Once I ... I was about eight years old, when I had a vision of my own, that ...
(Date:8/15/2017)... Los Angeles, CA (PRWEB) , ... August 15, 2017 , ... The city of Los ... styles exist in harmony with “Cali Style”. LA’s Top Style List, a website that spotlights ... to help the public wear their wardrobe all year long. , According to the senior ...
(Date:8/15/2017)... ... August 15, 2017 , ... The V Foundation ... 19th Annual V Foundation Wine Celebration raised nearly $9 million for cancer research ... million in “Fund-A-Need” donations to support the study of BRCA mutation research in ...
Breaking Medicine News(10 mins):
(Date:7/27/2017)... WARSAW, Ind., July 27, 2017  Zimmer Biomet Holdings, ... the quarter ended June 30, 2017.  The Company reported ... of 1.1% over the prior year period, and an ... approximately 240 basis points of contribution from the LDR ... from the second quarter of 2016, or 0.3% on ...
(Date:7/26/2017)... Fla. , July 26, 2017 Sancilio ... enrollment of our clinical trial evaluating Altemia TM , ... Anemia (SCA) and Sickle Cell Disease (SCD). The SCOT ... evaluate the efficacy and safety of Altemia TM ... is conducted under US IND 125274. ...
(Date:7/24/2017)... N.Y. , July 24, 2017 IBM (NYSE: ... the Gartner Magic Quadrant for Solid-State Arrays (SSA) for the ... According to Gartner, "Vendors in the Leaders ... and Completeness of Vision. A vendor in the Leaders quadrant ... needed to drive the acceptance of new technologies. These vendors ...
Breaking Medicine Technology: